Neratinib/Neratinib vs. Pyrotinib: Similarities and Differences between Two Breast Cancer Treatment Drugs

Neratinib/ Neratinib and Pyrotinib are both targeted drugs in the field of breast cancer treatment. Although they have certain similarities in structure and mechanism of action, they show unique differences in indications, clinical applications and side effects.

Neratinib is an irreversible tyrosine kinase inhibitor (TKI) targetingHER1, HER2 and HER4. It has been approved by the U.S. Food and Drug Administration (FDA) for the extended adjuvant treatment of patients with early-stage HER2-overexpressing or amplified breast cancer after surgery and trastuzumab-based adjuvant therapy. The mechanism of action of neratinib is by covalently binding to cysteine u200bu200bresidues in the ATP-binding domains of HER1, HER2, and HER4, thereby inhibiting the phosphorylation of the ErbB family and its downstream pathways (such as ERK and Akt). This process effectively blocks the activity of the HER2 receptor family, thereby inhibiting the proliferation and spread of breast cancer cells.

Pyrote is a new generation of anti-HER2-targeted drug independently developed in China. It has received conditional approval from the National Medical Products Administration in combination with capecitabine for the treatment of patients with HER2-positive advanced or metastatic breast cancer, particularly those who have previously received anthracycline or taxane chemotherapy. Pyrotinib is also a small molecule, irreversible bi-pan-ErbB TKI active on HER1, HER2 and HER4. Its mechanism of action is similar to that of neratinib, which aims to block the HER family signaling pathway, inhibit the activation of tumor cell cycle and limit the development of tumors.

Although these two drugs have similarities in their mechanisms of action, they differ in their side effects. Diarrhea is one of the most common side effects of both TKI drugs, but is mostly mild to moderate. In addition, neratinib may also cause uncomfortable symptoms such as headache and dizziness, while pyrotinib may cause hematological toxic reactions such as leukopenia. These differences require physicians to make trade-offs and decisions based on the patient's specific circumstances when selecting medications.